The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
BIOE · Healthcare · Narrow moat
On the watchlist
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
| Measure | BIOE | NAGE | CDRE | IMAX |
|---|---|---|---|---|
| Moat Score (0–100) | 61 | 62 (highest) | 61 | 61 |
| Methodology version | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 |
| Business trend | 65 | 85 | 89 (highest) | 80 |
| Pricing power | 57 | 91 (highest) | 68 | 66 |
| Returns on capital | — | 8 | 52 (highest) | 35 |
| Balance-sheet safety | 99 | 100 (highest) | 71 | 51 |
| Capital allocation | 24 | 24 | 28 | 74 (highest) |
| No price data | No price data | 150% above value if growth stopped today (largest discount to value if growth stopped today) | 167% above value if growth stopped today | |
| Market cap | $10.3M | $256M | $1.3B | $2.3B |
| Moat tier | Narrow moat | Narrow moat | Narrow moat | Narrow moat |
| Filing date | FY2025 | FY2025 | FY2025 | FY2025 |